Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors

Br J Haematol. 2022 Apr;197(1):e1-e4. doi: 10.1111/bjh.18001. Epub 2021 Dec 19.
No abstract available

Keywords: CML; COVID-19; SARS-CoV-2; TKI; vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Protein Kinase Inhibitors